Deal Announcements
Antiva Biosciences Adds Series B Venture Capital
Monday, August 10, 2015 5:33:00 AM PDT | VentureDeal
Del Mar, California -- Biotechnology company Antiva Biosciences (no website) has secured $16 million in its second round of institutional venture capital funding.
Antiva is developing ABI-1968, its compound for the treatment of HPV.
The company has additional molecules that it is developing to target HIV, the herpes virus, the cytomegalovirus and others.
Canaan Partners and Sofinnova Ventures co-led the round.
The company said it would use the funding to advance its lead compound through Phase 1 clinical trials.
Email Page | 
Print Page